348 related articles for article (PubMed ID: 24848850)
1. Evaluation of tumor microvascular response to brivanib by dynamic contrast-enhanced 7-T MRI in an orthotopic xenograft model of hepatocellular carcinoma.
Song KD; Choi D; Lee JH; Im GH; Yang J; Kim JH; Lee WJ
AJR Am J Roentgenol; 2014 Jun; 202(6):W559-66. PubMed ID: 24848850
[TBL] [Abstract][Full Text] [Related]
2. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
Huynh H; Ngo VC; Fargnoli J; Ayers M; Soo KC; Koong HN; Thng CH; Ong HS; Chung A; Chow P; Pollock P; Byron S; Tran E
Clin Cancer Res; 2008 Oct; 14(19):6146-53. PubMed ID: 18829493
[TBL] [Abstract][Full Text] [Related]
3. Combining dynamic contrast enhanced magnetic resonance imaging and microvessel density to assess the angiogenesis after PEI in a rabbit VX2 liver tumor model.
Chen J; Qian T; Zhang H; Wei C; Meng F; Yin H
Magn Reson Imaging; 2016 Feb; 34(2):177-82. PubMed ID: 26518059
[TBL] [Abstract][Full Text] [Related]
4. Dynamic contrast-enhanced (DCE) MRI assessment of microvascular characteristics in the murine orthotopic pancreatic cancer model.
Wu L; Lv P; Zhang H; Fu C; Yao X; Wang C; Zeng M; Li Y; Wang X
Magn Reson Imaging; 2015 Jul; 33(6):737-60. PubMed ID: 25169584
[TBL] [Abstract][Full Text] [Related]
5. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
[TBL] [Abstract][Full Text] [Related]
6. Characterization of brivanib therapy response in hepatocellular carcinoma xenografts using ¹H HR-MAS spectroscopy and histopathology.
Yang J; Song KD; Kim JH; Im GH; Yoon S; Namgung M; Hwang JH; Lee JH; Choi D
Mol Med Rep; 2013 Nov; 8(5):1425-31. PubMed ID: 24064967
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy.
Akisik MF; Sandrasegaran K; Bu G; Lin C; Hutchins GD; Chiorean EG
Radiology; 2010 Aug; 256(2):441-9. PubMed ID: 20515976
[TBL] [Abstract][Full Text] [Related]
8. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
Wilmes LJ; Pallavicini MG; Fleming LM; Gibbs J; Wang D; Li KL; Partridge SC; Henry RG; Shalinsky DR; Hu-Lowe D; Park JW; McShane TM; Lu Y; Brasch RC; Hylton NM
Magn Reson Imaging; 2007 Apr; 25(3):319-27. PubMed ID: 17371720
[TBL] [Abstract][Full Text] [Related]
9. Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil.
Hsu CY; Shen YC; Yu CW; Hsu C; Hu FC; Hsu CH; Chen BB; Wei SY; Cheng AL; Shih TT
J Hepatol; 2011 Oct; 55(4):858-65. PubMed ID: 21338641
[TBL] [Abstract][Full Text] [Related]
10. [Effects of melittin on growth and angiogenesis of human hepatocellular carcinoma BEL-7402 cell xenografts in nude mice].
Song CC; Lu X; Cheng BB; DU J; Li B; Ling CQ
Ai Zheng; 2007 Dec; 26(12):1315-22. PubMed ID: 18076793
[TBL] [Abstract][Full Text] [Related]
11. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma.
Park JW; Finn RS; Kim JS; Karwal M; Li RK; Ismail F; Thomas M; Harris R; Baudelet C; Walters I; Raoul JL
Clin Cancer Res; 2011 Apr; 17(7):1973-83. PubMed ID: 21349999
[TBL] [Abstract][Full Text] [Related]
12. Dynamic contrast enhanced MR imaging for evaluation of angiogenesis of hepatocellular nodules in liver cirrhosis in N-nitrosodiethylamine induced rat model.
Zhang W; Chen HJ; Wang ZJ; Huang W; Zhang LJ
Eur Radiol; 2017 May; 27(5):2086-2094. PubMed ID: 27488851
[TBL] [Abstract][Full Text] [Related]
13. Dual-input two-compartment pharmacokinetic model of dynamic contrast-enhanced magnetic resonance imaging in hepatocellular carcinoma.
Yang JF; Zhao ZH; Zhang Y; Zhao L; Yang LM; Zhang MM; Wang BY; Wang T; Lu BC
World J Gastroenterol; 2016 Apr; 22(13):3652-62. PubMed ID: 27053857
[TBL] [Abstract][Full Text] [Related]
14. Noninvasive monitoring of microvascular changes with partial irradiation using dynamic contrast-enhanced and blood oxygen level-dependent magnetic resonance imaging.
Lin YC; Wang JJ; Hong JH; Lin YP; Lee CC; Wai YY; Ng SH; Wu YM; Wang CC
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1367-74. PubMed ID: 23195777
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activities of Liver-targeting peptide modified Recombinant human Endostatin in BALB/c-nu mice with Hepatocellular carcinoma.
Yan M; Dongmei B; Jingjing Z; Xiaobao J; Jie W; Yan W; Jiayong Z
Sci Rep; 2017 Oct; 7(1):14074. PubMed ID: 29075040
[TBL] [Abstract][Full Text] [Related]
16. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma.
Finn RS; Kang YK; Mulcahy M; Polite BN; Lim HY; Walters I; Baudelet C; Manekas D; Park JW
Clin Cancer Res; 2012 Apr; 18(7):2090-8. PubMed ID: 22238246
[TBL] [Abstract][Full Text] [Related]
17. Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepatocellular carcinoma treated with an antiangiogenic agent: a preliminary study.
Wang J; Chen LT; Tsang YM; Liu TW; Shih TT
AJR Am J Roentgenol; 2004 Sep; 183(3):713-9. PubMed ID: 15333360
[TBL] [Abstract][Full Text] [Related]
18. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
[TBL] [Abstract][Full Text] [Related]
19. The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases.
El-Khoueiry A; Posey JA; Castillo Ferrando JR; Krishnamurthi SS; Syed S; Kollia G; Walters I; Fischer BS; Masson E
Cancer Chemother Pharmacol; 2013 Jul; 72(1):53-64. PubMed ID: 23719718
[TBL] [Abstract][Full Text] [Related]
20. [Inhibitory effect of compound cantharides capsule on the proliferation of xenografts of human hepatocellular carcinoma HepG(2)215 in mice].
Han JJ; Yu JM; Wu HY; Liu JB; Song B; Xue DW
Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):821-5. PubMed ID: 23291129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
